Allergan Inc. (AGN) has agreed to pay Map Pharmaceuticals Inc. (MAPP) $60 million under a collaboration deal involving the latter's Levadex migraine drug.

Map plans to file for approval of the treatment in the first half of this year. Levadex is an inhaled version of a drug administered for decades in emergency rooms and doctors' offices through an intravenous line.

The pair plan to take advantage of Allergan's existing sales force dedicated to headache specialists. Last year, Allergan's Botox--used for medical purposes as well as for fighting wrinkles--was approved for marketing in the U.S. to treat migraines.

Allergan agreed to pay Map up to an additional $97 million for reaching regulatory milestones associated with the initial indication. The companies will jointly develop Levadex for additional indications.

Allergan closed Friday at $69.08 while Map finished at $15.50. Neither was active premarket.

-By Matt Jarzemsky, Dow Jones Newswires; 212-416-2240; matthew.jarzemsky@dowjones.com

 
 
Map Pharmaceuticals, Inc. (MM) (NASDAQ:MAPP)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Map Pharmaceuticals, Inc. (MM) Charts.
Map Pharmaceuticals, Inc. (MM) (NASDAQ:MAPP)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Map Pharmaceuticals, Inc. (MM) Charts.